Scleroderma dermal microvascular endothelial cells exhibit defective response to pro-angiogenic chemokines

Rheumatology (United Kingdom)

Volumn 55, Issue 4, 2016, Pages 745-754

  Tsou, Pei Suen ^a   Rabquer, Bradley J ^b,c   Ohara, Ray A ^b   Stinson, William A ^b   Campbell, Phillip L ^b   Amin, M Asif ^b   Balogh, Beatrix ^b   Zakhem, George ^b   Renauer, Paul A ^b   Lozier, Ann ^b   Arasu, Eshwar ^b   Haines, G Kenneth ^d   Kahaleh, Bashar ^e   Schiopu, Elena ^a   Khanna, Dinesh ^a   Koch, Alisa E ^b,f  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c ALBION COLLEGE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TOLEDO MEDICAL CENTER   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Chemokines; Scleroderma

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CXCR2; CXCL3 CHEMOKINE; FIBROBLAST GROWTH FACTOR 2; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INHIBITOR OF DNA BINDING PROTEIN 1; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ARTICLE; CELL CULTURE; CELL MIGRATION; CHEMOTAXIS; CHEMOTAXIS ASSAY; CONTROLLED STUDY; DERMAL MICROVASCULAR ENDOTHELIAL CELL; DISEASE DURATION; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCLERODERMA; SIGNAL TRANSDUCTION; SKIN BIOPSY;

EID: 84963757091     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev399     Document Type: Article

References (38)

1. Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 2013;65:1953-62.
2. LeRoy EC. Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 1996;22:675-94.
3. Rabquer BJ, Koch AE. Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts. Curr Rheumatol Rep 2012;14:56-63.
4. Szekanecz Z, Koch AE. Vascular involvement in rheumatic diseases: 'vascular rheumatology'. Arthritis Res Ther 2008;10:224.
5. Koch AE, Polverini PJ, Kunkel SL et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992;258:1798-801.
6. Strieter RM, Polverini PJ, Kunkel SL et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995;270:27348-57.
7. Isozaki T, Arbab AS, Haas CS et al. Evidence that CXCL16 is a potent mediator of angiogenesis and is involved in endothelial progenitor cell chemotaxis: studies in mice with K/BxN serum-induced arthritis. Arthritis Rheum 2013;65:1736-46.
8. Ruth JH, Haas CS, Park CC et al. CXCL16-mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent upon the MAPK pathway. Arthritis Rheum 2006;54:765-78.
9. Rabquer BJ, Tsou PS, Hou Y et al. Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis. Arthritis Res Ther 2011;13:R18.
10. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
11. Delia D, Lampugnani MG, Resnati M et al. CD34 expression is regulated reciprocally with adhesion molecules in vascular endothelial cells in vitro. Blood 1993;81:1001-8.
12. Fina L, Molgaard HV, Robertson D et al. Expression of the CD34 gene in vascular endothelial cells. Blood 1990;75:2417-26.
13. Hellwig SM, Damen CA, van Adrichem NP et al. Endothelial CD34 is suppressed in human malignancies: role of angiogenic factors. Cancer Lett 1997;120:203-11.
14. D'Alessio S, Fibbi G, Cinelli M et al. Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum 2004;50:3275-85.
15. Giusti B, Fibbi G, Margheri F et al. A model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients. Arthritis Res Ther 2006; 8:R115.
16. Margheri F, Serrati S, Lapucci A et al. Modulation of the angiogenic phenotype of normal and systemic sclerosis endothelial cells by gain-loss of function of pentraxin 3 and matrix metalloproteinase 12. Arthritis Rheum 2010;62:2488-98.
17. Sakurai D, Tsuchiya N, Yamaguchi A et al. Crucial role of inhibitor of DNA binding/differentiation in the vascular endothelial growth factor-induced activation and angiogenic processes of human endothelial cells. J Immunol 2004;173:5801-9.
18. Koch AE, Kronfeld-Harrington LB, Szekanecz Z et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease. Pathobiology 1993;61:239-46.
19. Furuse S, Fujii H, Kaburagi Y et al. Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis. J Rheumatol 2003;30:1524-8.
20. Cipriani P, Franca Milia A, Liakouli V et al. Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: pathogenetic implications. Arthritis Rheum 2006;54:3022-33.
21. Macko RF, Gelber AC, Young BA et al. Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation. J Rheumatol 2002;29: 2565-70.
22. Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 2002;90:1243-50.
23. Jiang BH, Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 2009;102:19-65.
24. Zhu S, Evans S, Yan B et al. Transcriptional regulation of Bim by FOXO3a and Akt mediates scleroderma seruminduced apoptosis in endothelial progenitor cells. Circulation 2008;118:2156-65.
25. Benezra R, Davis RL, Lockshon D, Turner DL, Weintraub H. The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 1990;61:49-59.
26. Ogata T, Wozney JM, Benezra R, Noda M. Bone morphogenetic protein 2 transiently enhances expression of a gene, Id (inhibitor of differentiation), encoding a helixloop-helix molecule in osteoblast-like cells. Proc Natl Acad Sci USA 1993;90:9219-22.
27. Hollnagel A, Oehlmann V, Heymer J, Ruther U, Nordheim A. Id genes are direct targets of bone morphogenetic protein induction in embryonic stem cells. J Biol Chem 1999;274:19838-45.
28. Lyden D, Young AZ, Zagzag D et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 1999;401:670-7.
29. Sakurai D, Yamaguchi A, Tsuchiya N, Yamamoto K, Tokunaga K. Expression of ID family genes in the synovia from patients with rheumatoid arthritis. Biochem Biophys Res Commun 2001;284:436-42.
30. Kim HJ, Chung H, Yoo YG et al. Inhibitor of DNA binding 1 activates vascular endothelial growth factor through enhancing the stability and activity of hypoxia-inducible factor-1alpha. Mol Cancer Res 2007;5:321-9.
31. Ling MT, Lau TC, Zhou C et al. Overexpression of Id-1 in prostate cancer cells promotes angiogenesis through the activation of vascular endothelial growth factor (VEGF). Carcinogenesis 2005;26:1668-76.
32. Volpert OV, Pili R, Sikder HA et al. Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Cancer Cell 2002;2:473-83.
33. Good DJ, Polverini PJ, Rastinejad F et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990;87:6624-8.
34. Ruzinova MB, Schoer RA, Gerald W et al. Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell 2003;4:277-89.
35. Valdimarsdottir G, Goumans MJ, Rosendahl A et al. Stimulation of Id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells. Circulation 2002;106:2263-70.
36. Wang Y, Kahaleh B. Epigenetic repression of bone morphogenetic protein receptor II expression in scleroderma. J Cell Mol Med 2013;17:1291-9.
37. Isozaki T, Amin MA, Arbab AS et al. Inhibitor of DNA binding 1 as a secreted angiogenic transcription factor in rheumatoid arthritis. Arthritis Res Ther 2014;16:R68.
38. Edhayan G, Ha CM, Ohara RA et al. Inflammatory properties of inhibitor of DNA binding 1 as a unique fibroblast derived nuclear protein. Arthritis Rheum 2014;66:S863.